Open AccessPrevalence and Risk Factors for Neutralizing Antibodies to Human Papillomavirus Types 16 and 18 in HIV-Positive Men Who Have Sex With Men
Author(s) -
Rahul Swarup Sharma,
Jimmy T. Efird,
Aung Chein,
Elizabeth A. Holly,
Mel Krajden,
J. Michael Berry,
Teresa M. Darragh,
Naomi Jay,
Joel M. Palefsky
Publication year - 2013
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e3182a7acd2
Subject(s) - medicine , men who have sex with men , anal cancer , vaccination , antibody , hpv infection , squamous intraepithelial lesion , papillomaviridae , prospective cohort study , immunology , gynecology , cancer , cervical cancer , human immunodeficiency virus (hiv) , cervical intraepithelial neoplasia , syphilis
Human papillomavirus (HPV) vaccination is routinely recommended in HIV-positive men who have sex with men (MSM) aged ≤ 26 years. Levels of previous HPV exposure in older HIV-positive MSM are assumed to be too high to warrant routine HPV vaccination. However, little is known about the prevalence of and risk factors for neutralizing antibody seropositivity to HPV-16 or HPV-18, a key measure of previous exposure to these types.